Abstract:<p>With rapid lifestyle transitions, the increasing burden of nonalcoholic fatty liver disease (NAFLD) in China has emerged as a major public health issue. To obtain a comprehensive overview of the status of NAFLD over the past decade, we evaluated the epidemiology, risk factors, complications, and management of NAFLD in China through a systematic review and meta‐analysis. Five English literature databases and three Chinese databases were searched for relevant topics from 2008 to 2018. A total of 392 studies were included, with a population of 2,054,554 from 28 provinces and districts. National prevalence of NAFLD was 29.2%, with a heavier disease burden among the middle‐aged, males, those in northwest China and Taiwan, regions with a gross domestic product (GDP) per capita greater than 100,000 yuan, and Uygur and Hui ethnic groups. Currently, original studies on natural history and complications of NAFLD in China are scarce. Several studies revealed NAFLD is positively correlated with the incidence of extrahepatic tumors, diabetes, cardiovascular disease (CVD) and metabolic syndrome (MetS). The Chinese population may have a higher hereditary risk of NAFLD due to more frequent nonsynonymous mutations in genes regulating lipid metabolism. Ultrasonography is the primary imaging tool in the detection of NAFLD in China. Serum tests and risk stratification algorithms for staging NAFLD remain under investigation. Specific pharmaceutical treatments for NAFLD are still undergoing clinical trials. It is noteworthy that the Chinese are underrepresented compared to their proportion of the NAFLD population in such trials.</p><h3> Conclusion</h3><p>China experienced an unexpected rapid increase in the burden of NAFLD over a short period. Rising awareness and urgent actions need to be taken in order to control the NAFLD pandemic in China.</p><p>This article is protected by copyright. All rights reserved.</p><p>With rapid lifestyle transitions, the increasing burden of nonalcoholic fatty liver disease (NAFLD) in China has emerged as a major public health issue. To obtain a comprehensive overview of the status of NAFLD over the past decade, we evaluated the epidemiology, risk factors, complications, and management of NAFLD in China through a systematic review and meta‐analysis. Five English literature databases and three Chinese databases were searched for relevant topics from 2008 to 2018. A total of 392 studies were included, with a population of 2,054,554 from 28 provinces and districts. National prevalence of NAFLD was 29.2%, with a heavier disease burden among the middle‐aged, males, those in northwest China and Taiwan, regions with a gross domestic product (GDP) per capita greater than 100,000 yuan, and Uygur and Hui ethnic groups. Currently, original studies on natural history and complications of NAFLD in China are scarce. Several studies revealed NAFLD is positively correlated with the incidence of extrahepatic tumors, diabetes, cardiovascular disease (CVD) and metabolic syndrome (MetS). The Chinese population may have a higher hereditary risk of NAFLD due to more frequent nonsynonymous mutations in genes regulating lipid metabolism. Ultrasonography is the primary imaging tool in the detection of NAFLD in China. Serum tests and risk stratification algorithms for staging NAFLD remain under investigation. Specific pharmaceutical treatments for NAFLD are still undergoing clinical trials. It is noteworthy that the Chinese are underrepresented compared to their proportion of the NAFLD population in such trials.</p><h3> Conclusion</h3><p>China experienced an unexpected rapid increase in the burden of NAFLD over a short period. Rising awareness and urgent actions need to be taken in order to control the NAFLD pandemic in China.</p><p>This article is protected by copyright. All rights reserved.</p>

NAFLD incidence is increasing

Sex-specific Metabolic Risk Factors and Their Trajectories Towards the Non-Alcoholic Fatty Liver Disease Incidence.

Prevalence and Risk Factors for the Development of Nonalcoholic Fatty Liver Disease in a Nonobese Chinese Population: the Zhejiang Zhenhai Study.

Is Cigarette Smoking an Independent Risk Factor or a Cofactor for Nonalcoholic Fatty Liver Disease?

Worldwide long-term trends in the incidence of nonalcoholic fatty liver disease during 1990–2019: A joinpoint and age-period-cohort analysis

2019 Global NAFLD Prevalence: A Systematic Review and Meta-analysis

Global burden of adult non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) has been steadily increasing over the past decades and is expected to persist in the future

Prevalence of Nonalcoholic Fatty Liver Disease and Economy

Risk for the Development of Non-Alcoholic Fatty Liver Disease: A Prospective Study.

Unexpected Rapid Increase in the Burden of NAFLD in China From 2008 to 2018: A Systematic Review and Meta‐Analysis

Baseline and change in serum lipid and uric acid level over time and incident of nonalcoholic fatty liver disease (NAFLD) in Chinese adults

The burden of nonalcoholic fatty liver disease (NAFLD) is rapidly growing in every region of the world from 1990 to 2019

Nonalcoholic fatty liver in Asia: Firmly entrenched and rapidly gaining ground

Review article: the epidemiologic burden of non‐alcoholic fatty liver disease across the world

Increasing prevalence of NAFLD/NASH among children, adolescents and young adults from 1990 to 2017: a population-based observational study.

Increased Risk of Low Bone Mineral Density in Patients with Non-Alcoholic Fatty Liver Disease: A Cohort Study

Epidemiology of alcoholic and nonalcoholic fatty liver disease in China

Risk factors and biomarkers of non-alcoholic fatty liver disease: an observational cross-sectional population survey

Increased NAFLD risk in newly diagnosed patients with RA during the first 4 years of follow-up: a nationwide, population-based cohort study

Influence of Nonalcoholic Fatty Liver Disease With Increased Liver Enzyme Levels on the Risk of Cirrhosis and Hepatocellular Carcinoma

The Prevalence and Risk Factors on Different Degrees of Non-Alcoholic Fatty Liver Disease in Shanghai